Carregant...
Bioactive nanotherapeutic trends to combat triple negative breast cancer
The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, and sacituzumab can tackle the breast cancer prognosis and/or progression, but achiev...
Guardat en:
| Publicat a: | Bioact Mater |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
KeAi Publishing
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970221/ https://ncbi.nlm.nih.gov/pubmed/33778204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bioactmat.2021.02.037 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|